These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37681450)

  • 1. Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia.
    Cornely OA; Ostermann H; Koehler P; Teschner D; Limburg E; Kramer WG; Barbat SH; Tawadrous M; Hodges MR
    J Antimicrob Chemother; 2023 Nov; 78(11):2645-2652. PubMed ID: 37681450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers.
    Hodges MR; Ople E; Wedel P; Shaw KJ; Jakate A; Kramer WG; Marle SV; van Hoogdalem EJ; Tawadrous M
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0162322. PubMed ID: 36988461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants.
    Hodges MR; Hazel S; Kramer WG; van Hoogdalem E-J; van Marle S; Tawadrous M; Jakate A
    Antimicrob Agents Chemother; 2024 May; 68(5):e0145523. PubMed ID: 38551346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis.
    Alkhazraji S; Gebremariam T; Alqarihi A; Gu Y; Mamouei Z; Singh S; Wiederhold NP; Shaw KJ; Ibrahim AS
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
    Cornely OA; Robertson MN; Haider S; Grigg A; Geddes M; Aoun M; Heinz WJ; Raad I; Schanz U; Meyer RG; Hammond SP; Mullane KM; Ostermann H; Ullmann AJ; Zimmerli S; Van Iersel MLPS; Hepler DA; Waskin H; Kartsonis NA; Maertens J
    J Antimicrob Chemother; 2017 Dec; 72(12):3406-3413. PubMed ID: 28961714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of
    Petraitiene R; Petraitis V; Maung BBW; Mansbach RS; Hodges MR; Finkelman MA; Shaw KJ; Walsh TJ
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33361304
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis.
    Wiederhold NP; Najvar LK; Shaw KJ; Jaramillo R; Patterson H; Olivo M; Catano G; Patterson TF
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections.
    Shaw KJ; Ibrahim AS
    J Fungi (Basel); 2020 Oct; 6(4):. PubMed ID: 33105672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
    Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
    Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
    DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
    Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial.
    Groll AH; Abdel-Azim H; Lehrnbecher T; Steinbach WJ; Paschke A; Mangin E; Winchell GA; Waskin H; Bruno CJ
    Int J Antimicrob Agents; 2020 Sep; 56(3):106084. PubMed ID: 32682946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of analogs of the Gwt1 inhibitor manogepix (APX001A) and in vitro evaluation against Cryptococcus spp.
    Trzoss M; Covel JA; Kapoor M; Moloney MK; Soltow QA; Webb PJ; Shaw KJ
    Bioorg Med Chem Lett; 2019 Dec; 29(23):126713. PubMed ID: 31668974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.
    Annino L; Chierichini A; Anaclerico B; Finolezzi E; Norata M; Cortese S; Cassetta MI; Fallani S; Novelli A; Girmenia C
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2596-602. PubMed ID: 23529741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
    Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
    Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus.
    Gebremariam T; Alkhazraji S; Alqarihi A; Wiederhold NP; Shaw KJ; Patterson TF; Filler SG; Ibrahim AS
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32205345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants.
    Hodges MR; van Marle S; Kramer WG; Ople E; Tawadrous M; Jakate A
    Antimicrob Agents Chemother; 2024 May; ():e0165023. PubMed ID: 38757982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections.
    Wu D; Mi Y; Weng J; Zhuang J; Ke X; Wang C; Liu K; Martinho M; Winchell GA; Zang Y; Xu L
    Adv Ther; 2022 Apr; 39(4):1697-1710. PubMed ID: 35167031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.